Back to results
US 2020/0347044 A1Published application
Compounds for Treating Rac-GTPase Mediated Disorder
AssigneeChildren’s Medical Center Corporation
InventorDavid A Williams
Life of this patent
Estimating the term…
Abstract
This disclosure relates to certain compounds that are effective in the treatment of a Rac-GTPase mediated disorder (e.g., acute lymphoblastic or chronic myelogenous leukemia), as well as methods for the manufacture of and the use of these compounds (e.g., for treating a Rac-GTPase mediated disorder).
Claims32
A compound of formula (I) or a salt thereof:
- wherein
- n is 0, 1, 2, 3, or 4;
- m is 0, 1, 2, 3, or 4;
- each of R1, R2, R3, R4, and R5, independently, is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, halo, ORa, SRa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, S(O)2NRaRb, or NRaRb;
- each of R6, independently, is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, halo, ORa, SRa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, S(O)2NRaRb, or NRaRb;
- each of R7, independently, is C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, halo, ORa, SRa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, S(O)2NRaRb, or NRaRb;
- each Ra independently, is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl;
- and each Rb, independently, is H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl.
5 more elements
9-23. (canceclled)
25-35. (canceled)
Dependencies are inferred from the claim text.